Effect of direct-acting antivirals on elastographic measures in patients with chronic hepatitis C virus infection
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2090-9098
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Effect of direct-acting antivirals on elastographic measures in patients with chronic hepatitis C virus infection ; volume:31 ; number:4 ; day:18 ; month:8 ; year:2020 ; pages:473-479 ; date:12.2019
The Egyptian Journal of Internal Medicine ; 31, Heft 4 (18.8.2020), 473-479, 12.2019
- Urheber
-
Sakr, Mohamed M.
El-Agrody, Ahmed I.
Farrag, Hesham A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.4103/ejim.ejim_43_19
- URN
-
urn:nbn:de:101:1-2021060508465484666938
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sakr, Mohamed M.
- El-Agrody, Ahmed I.
- Farrag, Hesham A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
Hepatitis C clearance by direct-acting antivirals impacts glucose and lipid homeostasis
Direct-acting antivirals and visceral leishmaniasis: a case report
Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications
Impact of direct-acting antivirals on neuropsychiatric and neurocognitive dysfunction in chronic hepatitis C patients
Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease
Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017–2021
Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study
Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients
Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
Hepatitis C clearance by direct-acting antivirals impacts glucose and lipid homeostasis
Direct-acting antivirals and visceral leishmaniasis: a case report
Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications
Impact of direct-acting antivirals on neuropsychiatric and neurocognitive dysfunction in chronic hepatitis C patients
Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease
Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017–2021
Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study
Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients
Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
Hepatitis C clearance by direct-acting antivirals impacts glucose and lipid homeostasis
Direct-acting antivirals and visceral leishmaniasis: a case report
Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications
Impact of direct-acting antivirals on neuropsychiatric and neurocognitive dysfunction in chronic hepatitis C patients
Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease
Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017–2021
Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study